Evaluation of Platelet Reactivity in Diabetes Mellitus

Kutti, Jack; Wadenvik, Hans; Henestam, Birgitta; Stenström, Gunnar

doi:10.1111/j.0954-6820.1986.tb03298.x

Cited by 20 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The curves of the mean aggregate sizes and light transmission characteristics suggested that the rates of collagen-induced aggregation of isolated platelets in MetS patients significantly exceeded the corresponding values in group of healthy volunteers (Idrisova et al, 2007 ). Several publications suggest that platelet sensitivity in T2DM patients increases due to action of the various platelet aggregation inductors including ADP, thrombin, and collagen (Kutti et al, 1986 ; Bode-Böger et al, 1998 ; Tokuda et al, 2012 ). Correlation analysis reveals the presence of direct relationship between the glycated hemoglobin levels and the rates of collagen- and ADP-induced platelet aggregation activities (Rabini et al, 1998 ; Gruzdeva et al, 2008 ; Tokuda et al, 2012 ).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation

et al. 2015

View full text Add to dashboard Cite

Patients with metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM) have high risk of microcirculation complications and microangiopathies. An increase in thrombogenic risk is associated with platelet hyperaggregation, hypercoagulation, and hyperfibrinolysis. Factors leading to platelet activation in MetS and T2DM comprise insulin resistance, hyperglycemia, non-enzymatic glycosylation, oxidative stress, and inflammation. This review discusses the role of nitric oxide (NO) in the regulation of platelet adhesion and aggregation processes. NO is synthesized both in endotheliocytes, smooth muscle cells, macrophages, and platelets. Modification of platelet NO-synthase (NOS) activity in MetS patients can play a central role in the manifestation of platelet hyperactivation. Metabolic changes, accompanying T2DM, can lead to an abnormal NOS expression and activity in platelets. Hyperhomocysteinemia, often accompanying T2DM, is a risk factor for cardiovascular accidents. Homocysteine can reduce NO production by platelets. This review provides data on the insulin effects in platelets. Decrease in a number and sensitivity of the insulin receptors on platelets in T2DM can cause platelet hyperactivation. Various intracellular mechanisms of anti-aggregating insulin effects are discussed. Anti-aggregating effects of insulin are mediated by a NO-induced elevation of cGMP and upregulation of cAMP- and cGMP-dependent pathways. The review presents data suggesting an ability of platelets to synthesize humoral factors stimulating thrombogenesis and inflammation. Proinflammatory cytokines are considered as markers of T2DM and cardiovascular complications and are involved in the development of dyslipidemia and insulin resistance. The article provides an evaluation of NO-mediated signaling pathway in the effects of cytokines on platelet aggregation. The effects of the proinflammatory cytokines on functional activity of platelets are demonstrated.

show abstract

mentioning

confidence: 99%

“…Increased glycosylation of platelet proteins modulates cellular functions in diabetes. In particular, possible glycosylation of calmodulin that modulates activity of nitric oxide synthase (NOS) results in the decreased synthesis of nitric oxide (NO) (Kutti et al, 1986 ).…”

mentioning

confidence: 99%

Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Various mechanisms have been suggested to be responsible for this enhanced platelet activation and aggregation such as abnormal Ca 2+ -ATPase activity (Rosado et al, 2004;Jardin et al, 2006), impaired Ca 2+ homeostasis (Ishii et al, 1991), impairment in platelet signalling such as nitric oxide (NO) production (Trovati and Anfossi, 2002). However, in vitro studies by Kutti et al (1986) showed no increase in adenosine diphosphate (ADP) sensitivity of platelet from diabetic patients. According to Malik et al (2012), the reason for the contrasting result could be the fact that all the patients in the study by Kutti et al (1986) were insulin dependent diabetics.…”

Section: Resultsmentioning

confidence: 99%

“…However, in vitro studies by Kutti et al (1986) showed no increase in adenosine diphosphate (ADP) sensitivity of platelet from diabetic patients. According to Malik et al (2012), the reason for the contrasting result could be the fact that all the patients in the study by Kutti et al (1986) were insulin dependent diabetics. And as described by Harrison and his colleague (1980), chronic use of insulin administration may restore prostacyclin PGI2 production in platelets of diabetic animals leading to a decrease in their aggregation tendency.…”

Section: Resultsmentioning

confidence: 99%

Platelet function, anthropometric and metabolic variables in Nigerian Type 2 Diabetic patients

Jeje¹,

Shittu²,

Fasanmade³

2014

Afr. J. Biotechnol.

View full text Add to dashboard Cite

This study examined the effects of anthropometric variables and metabolic imbalance on platelet aggregation in diabetic patients. A total of 109 volunteer were used; 58 diabetes mellitus (DM) patients (28 males and 30 females) who were receiving treatment at the University College Hospital Ibadan and 51 non diabetic control recruited from residents of Agbowo and Teachers of some secondary schools within the University of Ibadan. Body mass index (BMI) and body surface area (BSA) were assessed as indices of anthropometry, fasting blood sugar (FBS), plasma cholesterol and triglycerides (TAG) were determined using standard method and platelet aggregation test was done on the whole blood. Platelet aggregation ratio was higher in non diabetic compared to the diabetic subjects (P<0.001). The mean platelet aggregation ratio was also significantly higher in the male diabetic when compared to the female diabetic group (P<0.001). There was a significant linear relationship between platelet aggregation ratio and BMI (P<0.01), age (P0.05), FBS (P< 0.01), plasma cholesterol (P<0.01) and plasma TAG (P<0.05). However, the correlation coefficient between platelet aggregation ratio and BSA is not significant. In the non diabetic control subjects the correlation coefficient is not significant. Findings from this study suggest that, the increased platelet aggregation found in diabetic patients increased significantly with increased BMI but decrease with age. The mean platelet aggregation is also increased significantly with increase metabolic imbalance.

show abstract

“…In the patient with diabetes, anti-aggregatory mechanisms in the endothelium are impaired (Ceriello 2004). Platelets are more susceptible to activation and aggregation (Kutti 1986) and antifibrinolytic activity is attenuated (Colwell 2003).…”

Section: Diabetes Cardiovascular Disease and The Role Of Plateletsmentioning

confidence: 99%

Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus

Valentine

Laar

Driel

2012

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Cardiovascular disease (CVD) is the most prevalent complication of type 2 diabetes with an estimated 65% of people with type 2 diabetes dying from a cause related to atherosclerosis. Adenosine-diphosphate (ADP) receptor antagonists like clopidogrel, ticlopidine, prasugrel and ticagrelor impair platelet aggregation and fibrinogen-mediated platelet cross-linking and may be effective in preventing CVD. Objectives To assess the effects of adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (issue 2, 2011), MEDLINE (until April 2011) and EMBASE (until May 2011). We also performed a manual search, checking references of original articles and pertinent reviews to identify additional studies. Selection criteria Randomised controlled trials comparing an ADP receptor antagonist with another antiplatelet agent or placebo for a minimum of 12 months in patients with diabetes. In particular, we looked for trials assessing clinical cardiovascular outcomes. Data collection and analysis Two review authors extracted data for studies which fulfilled the inclusion criteria, using standard data extraction templates. We sought additional unpublished information and data from the principal investigators of all included studies. Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus (Review)

show abstract

Evaluation of Platelet Reactivity in Diabetes Mellitus

Cited by 20 publications

References 21 publications

Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation

Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation

Platelet function, anthropometric and metabolic variables in Nigerian Type 2 Diabetic patients

Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus

Contact Info

Product

Resources

About